Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Share News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,440.00
Bid: 1,431.00
Ask: 1,433.00
Change: 12.00 (0.84%)
Spread: 2.00 (0.14%)
Open: 1,439.00
High: 1,448.00
Low: 1,417.00
Prev. Close: 1,428.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director dealings: Indivior execs snap up shares

Wed, 15th May 2019 15:41

(Sharecast News) - Indivior chief executive officer Sean Thaxter bought 100,000 shares at 44.64p each on Tuesday, leaving him with an interest of just over 1.6m shares.In addition to Thaxter's £44,640 purchase, two days before non-executive director Daniel Phelan bought 10,000 ADRs, representing 50,000 shares at an average price of $2.78 each, leaving him with an interest in 60,318 Shares, the company said in a statement.Tatjana May, another non-executive director, followed with another 22,309 shares at 44.58p each the next day, leaving her with 22,309 shares.Indivior shares got a boost on the back of the news that the drug developer's directors had been buying up its stock.The company, which makes opioid addiction treatment Suboxone, has been under intense pressure after it was hit with US fraud charges over a marketing scheme used to boost prescriptions of its opioid addiction drugs.At 1620 BST, Indivior shares were up 14.91% at 52p.Top Director BuysJardine Matheson Holdings Ltd (Singapore Reg) (JAR)Director name: Mr E P K WeatherallAmount purchased: 42,885 @ $63.24Value: $2,711,927 Victrex plc (VCT)Director name: Mr Jakob SigurdssonAmount purchased: 3,000 @ 2,091.76pValue: £62,753 Indivior (INDV)Director name: Mr Shaun ThaxterAmount purchased: 100,000 @ 44.64pValue: £44,640 Indivior (INDV)Director name: Mr Daniel J. PhelanAmount purchased: 50,000 @ 42.89pValue: £21,445 Top Director SellsInternational Consolidated Airlines Group SA (CDI) (IAG)Director name: Mr William Matthew WalshAmount sold: 350,000 @ 503.50pValue: £1,762,250 International Consolidated Airlines Group SA (CDI) (IAG)Director name: Mr William Matthew WalshAmount sold: 300,000 @ 504.00pValue: £1,512,000 International Consolidated Airlines Group SA (CDI) (IAG)Director name: Mr William Matthew WalshAmount sold: 300,000 @ 504.00pValue: £1,512,000 James Halstead (JHD)Director name: Mr Mark HalsteadAmount sold: 120,000 @ 508.00pValue: £609,600 International Consolidated Airlines Group SA (CDI) (IAG)Director name: Mr William Matthew WalshAmount sold: 50,000 @ 505.80pValue: £252,900 Arcontech Group (ARC)Director name: Mr Richard LastAmount sold: 100,000 @ 160.12pValue: £160,120 Arcontech Group (ARC)Director name: Mr Richard LastAmount sold: 25,000 @ 161.75pValue: £40,438 Arcontech Group (ARC)Director name: Mr Richard LastAmount sold: 25,000 @ 157.00pValue: £39,250
More News
16 Feb 2022 07:05

Indivior considers US listing after returning to profit

(Sharecast News) - Indivior said it was considering a US listing for its shares as the drugs company swung to an annual profit and predicted strong growth for its Sublocade opioid.

Read more
9 Feb 2022 16:02

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
28 Jan 2022 16:22

UPDATE: Indivior notes robust results for treatment in fentanyl trial

UPDATE: Indivior notes robust results for treatment in fentanyl trial

Read more
28 Jan 2022 14:53

CORRECT: Indivior notes results for painkiller in fentanyl trial

CORRECT: Indivior notes results for painkiller in fentanyl trial

Read more
28 Jan 2022 09:02

Indivior's painkiller demonstrates positive interaction with fentanyl

Indivior's painkiller demonstrates positive interaction with fentanyl

Read more
28 Jan 2022 07:55

Indivior welcomes results from buprenorphine-fentanyl interaction study

(Sharecast News) - Pharmaceutical company Indivior hailed the results of a study aimed at assessing the ability of its buprenorphine asset to reduce respiratory depression and apnea associated with the synthetic opioid fentanyl.

Read more
19 Nov 2021 14:56

EXECUTIVE CHANGES: Dechra Pharmaceuticals picks Alison Platt as chair

EXECUTIVE CHANGES: Dechra Pharmaceuticals picks Alison Platt as chair

Read more
10 Nov 2021 12:28

LONDON MARKET MIDDAY: Stocks rise as investors eye US inflation data

LONDON MARKET MIDDAY: Stocks rise as investors eye US inflation data

Read more
10 Nov 2021 10:12

IN BRIEF: Scopia sells 2.8% stake in Indivior for GBP50 million

IN BRIEF: Scopia sells 2.8% stake in Indivior for GBP50 million

Read more
10 Nov 2021 08:07

Indivior slumps as Scopia Capital sells 20m shares

(Sharecast News) - Indivior was under the cosh on Wednesday after US alternative asset management firm Scopia Capital sold 20m shares in the opioid addiction treatment maker in a placing.

Read more
1 Nov 2021 09:38

LONDON BROKER RATINGS: Upgrades for Lloyds Banking and NatWest

LONDON BROKER RATINGS: Upgrades for Lloyds Banking and NatWest

Read more
28 Oct 2021 13:23

Indivior lifts 2021 revenue guidance amid strong Sublocade sales

Indivior lifts 2021 revenue guidance amid strong Sublocade sales

Read more
28 Oct 2021 12:17

Indivior lifts FY guidance as Q3 profits, revenue jump

(Sharecast News) - Indivior lifted its full-year guidance on Thursday as it reported a rise in third-quarter revenue and profit.

Read more
24 Oct 2021 17:12

Sunday share tips: Light Science Technologies, Indivior

(Sharecast News) - The Financial Mail on Sunday's Midas column told readers to buy shares of Light Science Technologies, pointing out the benefits of the company's technology for health, climate and the UK more economy.

Read more
31 Aug 2021 09:38

LONDON BROKER RATINGS: Citi and JPMorgan differ on Bridgepoint

LONDON BROKER RATINGS: Citi and JPMorgan differ on Bridgepoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.